Evidence map›Paper›PMID 36411702›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2022

Mn-SOD alleviates methotrexate-related hepatocellular injury via GSK-3β affecting anti-oxidative stress of HO-1 and Drp1.

Zhuo Li, Mengxuan Chen, Weihang Wang, Qiyao Liu, Naiping Li, Bo He, Yongfang Jiang, Jing Ma

Open access · greenAbstract read
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Animals : an open access journal from MDPI · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhuo LiDepartment of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha 410011. lizhuo75@csu.edu.cn.
Mengxuan ChenDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Weihang WangDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Qiyao LiuDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Naiping LiDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Bo HeDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yongfang JiangDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Jing MaDepartment of Infectious Diseases, Second Xiangya Hospital, Central South University, Changsha 410011, China. jingma2003@csu.edu.cn.
Central South University · CN

Funding

the National Natural Science Foundation 81500455the Natural Science Foundation of Hunan Province 2022JJ30825 and 2020JJ4793the Project of Hunan Provincial Health Commission 202120700992
6 · The paper itself

Abstract

objectivesMethotrexate (MTX) is the most common therapeutic agent that may have the risk of drug-induced liver injury. Its pathogenic mechanism is related to oxidative stress caused by mitochondrial dysfunction. Superoxide dismutase (SOD), including manganese-containing SOD (Mn-SOD), can exert its effect of anti-oxidative stress by scavenging superoxide free radicals. Accordingly, this study is performed to explore the underlying molecular mechanism via observing whether Mn-SOD could affect the damage of MTX to hepatocytes.

methodsHuman hepatocyte cell line L-02 was cultured in vitro and divided into 4 groups, including a blank group with the addition of the same volume of serum-free medium, a MTX group (40 μg/well MTX drug-treatment), a MTX+NC group (40 μg/well MTX drug-treatment+blank plasmid), and a MTX+SOD group (40 μg/well MTX drug-treatment+Mn-SOD plasmid). The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and microRNA-122 (miR-122) in the supernatant of cell culture were respectively detected by automatic biochemical analytical instrument and real-time RT-PCR to evaluate the degree of hepatocyte damage in each group. MitoSOX fluorescent probe was used to label intracellular superoxide in each group, and cell apoptosis was detected by flow cytometry. Meanwhile, the contents of glycogen synthase kinase-3 beta (GSK-3β), hemeoxygenase-1 (HO-1), mitochondrial fission-mediated protein of dynamin-related protein 1 (Drp1), and Mn-SOD were detected by Western blotting.

resultsCompared with the blank group, the levels of ALT, AST, and miR-122 in the supernatant of hepatocyte culture of the MTX group and MTX+NC group were significantly elevated (all

conclusionsMTX may induce hepatocyte damage, and one of the mechanisms may be due to the decrease of intracellular Mn-SOD level, which can cause the accumulation of superoxide, affect the levels of HO-1 and Drp1 through GSK-3β leading to mitochondrial damage and cell apoptosis. High expression of Mn-SOD intracellularly through exogenous introduction can scavenge drug-produced superoxide, affect HO-1 and Drp1 levels through GSK-3β, activate mitochondria, protect cells against damage from oxidative stress, and inhibit hepatocyte apoptosis eventually. So exogenous introduction of SOD may be a potential therapeutic approach to block or reverse MTX-related hepatocyte injury.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsDynaminsGlycogen Synthase Kinase 3 betaHeme Oxygenase-1HumansMethotrexateOxidative StressSuperoxide DismutaseSuperoxidesDynaminsGlycogen Synthase Kinase 3 betaHeme Oxygenase-1HMOX1 protein, humanMethotrexateMicroRNAsMIRN122 microRNA, humanSuperoxide DismutaseSuperoxideshepatocellular injurymanganese superoxide dismutasemethotrexate

Identifiers

PMID36411702
PMCPMC10930320
OpenAlexW4309668381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.